Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 10, 1999

View Archived Issues

Pharmos: Q2 1999 highlights

Phase Ia results reported for Cell Pathways' novel SAAND

Medeva acquires additional European rights to ML Laboratories' MDPI device

Avanir submits info on topical herpes treatment for final review

U.S. study will investigate the effects of phytoestrogens on the human endometrium

SCRAS team evaluates topoisomerase inhibitors for cancer indications

Fujisawa announced setback in launch data for Protopic

Glaxo Wellcome files for approval of flu drug in Japan

NexMed reports promising phase I results with drug for FSD

NCI scientists initiate testing of thalidomide in colorectal cancer patients

Incara, Knoll terminate Bextra collaboration

Yamanouchi reports two new series of ICE inhibitors

Ortho-McNeil's delta-opioid receptor ligands have broad therapeutic potential

Novel prodrugs of HIV protease inhibitors with potential to increase patient compliance

Korean researchers synthesize anticancer platinum complexes

Bayer reveals antiinflammatory PDE4 inhibitors in patent literature

Levodopa prodrug TV-1203 is quickly and effectively hydrolyzed to active form following oral dosing

Long-term effects of adenosine A2A receptor blockade with Sch-58261 in parkinsonian rats

Ropinirole is associated with a 15% lower risk of dyskinesia than L-dopa in early-stage PD patients

Licensing opportunity from NIH: improved technology for radiotherapy of cancer and other diseases

Idec and NCI form partnership to broaden use of ibritumomab tiuxetan

Amerimmune to begin phase I/II study of AIDS drug in September

Orally active carbapenem prodrug OCA-983 synthesized and evaluated at Wyeth-Ayerst

S-33084: a potent and selective D3 antagonist and putative antipsychotic agent

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...